U.S. equities ended broadly lower on Wednesday, with gains concentrated in select mega-cap technology names while several large-cap stocks declined amid mixed corporate updates.
Arista Networks led the advance among stocks with market capitalizations above $200 billion, rising 4.66% to extend recent momentum. Arm also posted a 2.35% gain, contributing to the sector’s outperformance. The gains were partially offset by declines in other large-cap names, including Dycom Industries, which fell 11.01% despite beating earnings estimates on strong infrastructure demand, and Snap, which slid 9.12%.
Among mid-cap movers, Abercrombie & Fitch surged 31.59% following its latest quarterly results, while Biohaven Pharmaceutical Holding gained 25.38%. Losses were led by Generate Biomedicines, which dropped 17.76%, and Evolution Metals Tech, down 13.29%. In the small-cap segment, Capricor Therapeutics rose 9.89%, though Electromed fell 18.15% despite beating Q4 earnings expectations, and Qifu Technology declined 18.34% after a Morgan Stanley downgrade citing sector headwinds.
The mixed performance reflected ongoing volatility in technology and biopharma stocks, with several companies reporting results that diverged from market expectations. The S&P 500 and Nasdaq Composite each ended slightly lower for the session, while the Dow Jones Industrial Average showed modest gains.
Corporate updates continued to drive individual stock movements, with some companies benefiting from positive earnings surprises or strategic developments, while others faced pressure from downgrades or weaker-than-anticipated guidance.
